Clinical Trials Browser

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT06205953 2026-04-16

EUREKA

Recruiting

400 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06383143 2026-04-16

ProDigALIty

Recruiting

760 enrolled

Plasma cell

Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance

NCT04847453 2026-04-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Phase 1 Recruiting

24 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Phase 2 Recruiting

96 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05444920 2026-03-27

ITA-WebNet

Recruiting

1,000 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07081646 2026-03-24

ALACRITY

Phase 1/2 Recruiting

91 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT07250269 2026-03-24

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Phase 1 Recruiting

9 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01408225 2026-03-23

B-SCR-MM

Recruiting

5,000 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias

NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Phase NA Recruiting

41 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06627309 2026-03-09

Rapid dFLC Response Predict CHR in AL Amyloidosis

Recruiting

50 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06569147 2026-03-06

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

49 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07448779 2026-03-04

GlycAL

Recruiting

100 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Paraproteinemias

NCT07448935 2026-03-04

ALPS

Recruiting

100 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, POEMS Syndrome

NCT06963216 2026-02-27

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Phase 3 Recruiting

15 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT07172243 2026-02-27

BE.Amycon Biobank & Data Registry UZ Leuven

Recruiting

505 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Amyloid Neuropathies, Familial

NCT05145816 2026-02-17

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Phase 1/2 Recruiting

37 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Clinical Trials

ReAL

EUREKA

ProDigALIty

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

ITA-WebNet

ALACRITY

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

B-SCR-MM

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Rapid dFLC Response Predict CHR in AL Amyloidosis

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

GlycAL

ALPS

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

BE.Amycon Biobank & Data Registry UZ Leuven

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis